For instance, we reported that the antimetastatic activity of SAM in breast and prostate cancer is likely due to downregulation of pro-metastatic genes, such as urokinase plasminogen activator (uPA) and Matrix metallopeptidase 2 (MMP2) (6, 9). This evidence concerns the gene PLAU and prostate cancer.